Athersys, Inc. is a US-based biotech company developing stem cell treatments for neurological, inflammatory and immune and cardiovascular diseases. Its patented MultiStem candidate can be delivered to patients up to 36 hours after ischemic stroke – significantly opening up the window to treatment. Dr Robert William Mays is Head of Neurosciences and Vice President of Regenerative Medicine […]

The Food and Drug Administration (FDA) has cleared the way for Tonix Pharmaceuticals to begin a Phase II study of its therapeutic candidate, which intends to prevent migraine headaches. Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022. Tonix believes that TNX-1900, which works by stimulating oxytocin receptors in […]

Annovis Bio will target Alzheimer’s disease and Parkinson’s disease with two Phase III trials in early 2022, CEO Maria Maccecchini says. The Pennsylvania-based biotech has requested a meeting with the FDA for its Parkinson’s trial, and it intends to file a similar request for Alzheimer’s within the next two weeks, Maccecchini says, adding that a […]